{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"15"},{"groupId":"OG001","value":"2"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"26"},{"groupId":"OG001","value":"6"}],"units":"Participants"}],"description":"Medication Use change reported from baseline until of study. Medication use is quantified by \"morphine equivalent usage\" (measured separately from Responder/Non-responder definition for the primary endpoint)","groups":[{"description":"ExAblate 2000: MR guided focused ultrasound","id":"OG000","title":"ExAblate Treatment Arm"},{"description":"ExAblate 2000: MR guided focused ultrasound sham","id":"OG001","title":"ExAblate Sham Control Arm"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"Only 26 of the 81 subjects in ExAblate treatment arm and 6 of 26 in the sham arm were taking non-opioid medication at baseline.","reportingStatus":"POSTED","timeFrame":"3 months post treatment","title":"Number of Participants With a Change in Medication Use","type":"SECONDARY","unitOfMeasure":"Participants"}